Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Magnetic Stimulation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02704117 |
Recruitment Status :
Active, not recruiting
First Posted : March 9, 2016
Last Update Posted : December 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obsessive-Compulsive Disorder | Device: Transcranial Magentic Stimulation | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 19 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Neurocircuitry of OCD: Effects Of Modulation |
Study Start Date : | June 2015 |
Estimated Primary Completion Date : | September 2023 |
Estimated Study Completion Date : | October 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation applied over the pre-supplementary motor area (pSMA), for ten sessions, Monday through Friday, over the course of two weeks.
|
Device: Transcranial Magentic Stimulation
This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
Other Name: Continuous Theta Burst Stimulation (cTBS) |
- Change in activation of pre-supplementary motor area/dorsal anterior cingulate cortex (pSMA/dACC) on functional magnetic resonance imaging (fMRI) during the Multi-Source Interference task (MSIT) [ Time Frame: Baseline and 6 months ]
- Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) [ Time Frame: Baseline and 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Current primary OCD diagnosis and current Y-BOCS total score of ≥16
- 18-70 years of age
- Ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent
- No use of psychiatric medications or stable psychiatric medication use for a minimum of 6 week prior to study entry
- Ongoing psychotherapy allowed if already established for three months or more before study entry
Exclusion Criteria:
- History of primary psychotic disorder or bipolar disorder
- Present acute suicidality
- History of head injury, epilepsy, or other clinically significant neurological illness except tic disorders
- Active systemic medical (metabolic, endocrine, chronic inflammatory, vascular, autoimmune) disease
- Premorbid intelligence quotient (IQ) estimate < 80
- Visual disturbance (<20/40 Snellen visual acuity, corrected)
- Current, or alcohol or illicit substance abuse/dependence in the last 3 months
- Contraindications to TMS or MRI: metallic foreign objects, e.g., aneurysm clips/pacemakers, or questionable history of metal fragments, claustrophobia
- Women who are pregnant or breastfeeding. All women participants of reproductive age are required to have a negative pregnancy test prior to enrollment and use medically acceptable birth control throughout the study (barrier and/or oral contraceptives)
- Current psychotic symptoms
- An increased risk of seizure, determined by history
- Medications judged to notably affect cortical excitability e.g., anticonvulsants or high-dose benzodiazepines (> 4 mg/day of clonazepam or equivalent)
- Predominant hoarding symptoms

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02704117
United States, Rhode Island | |
Butler Hospital | |
Providence, Rhode Island, United States, 02906 |
Responsible Party: | Butler Hospital |
ClinicalTrials.gov Identifier: | NCT02704117 |
Other Study ID Numbers: |
P50MH106435 ( U.S. NIH Grant/Contract ) |
First Posted: | March 9, 2016 Key Record Dates |
Last Update Posted: | December 2, 2022 |
Last Verified: | December 2022 |
Compulsive Personality Disorder Obsessive-Compulsive Disorder Personality Disorders Mental Disorders Anxiety Disorders |